A Randomized, Double-Blind, Placebo-Controlled Dose Range Finding Study With Open-Label Extension to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of LMI070/Branaplam Administered as Weekly Oral Doses in Participants With Early Manifest Huntington's Disease
Latest Information Update: 06 Feb 2024
At a glance
- Drugs Branaplam (Primary)
- Indications Huntington's disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms VIBRANT-HD
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 04 Feb 2024 This trial has been discontinued in Italy, according to European Clinical Trials Database record.
- 04 Dec 2023 Status changed from active, no longer recruiting to completed.
- 16 Nov 2023 This trial has been completed in France, according to European Clinical Trials Database record.